Using the monoclonal antibody Nimotuzumab in treating patients with squamous cell carcinoma of head and neck in advanced stages.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 15 Sep 2016
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin; Fluorouracil
- Indications Head and neck cancer
- Focus Adverse reactions
- 11 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by Cuban Clinical Trial Registry.
- 06 Sep 2011 New trial record